Last reviewed · How we verify
Vunakizumab (IL-17A inhibitor)
Vunakizumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in immune-mediated inflammation.
Vunakizumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in immune-mediated inflammation. Used for Psoriasis, Psoriatic arthritis.
At a glance
| Generic name | Vunakizumab (IL-17A inhibitor) |
|---|---|
| Sponsor | Fujian Cancer Hospital |
| Drug class | IL-17A inhibitor (monoclonal antibody) |
| Target | IL-17A |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
IL-17A is a key driver of inflammatory and autoimmune responses. By neutralizing IL-17A, vunakizumab reduces the recruitment and activation of immune cells at sites of inflammation, thereby suppressing pathogenic inflammatory cascades. This mechanism is relevant for conditions where IL-17A-mediated inflammation plays a central pathogenic role.
Approved indications
- Psoriasis
- Psoriatic arthritis
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Injection site reactions
Key clinical trials
- A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy (PHASE2)
- Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus (PHASE1)
- Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
- Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |